A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
| 대상 질환 | Colitis, Ulcerative |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Janssen Research & Development, LLC |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 84 명 |
| 중재(약물) | Golimumab, Infliximab |
| 시작일 | 2018년 10월 29일 |
| 완료일 | 2023년 11월 21일 |
| 결과 공개일 | 2025년 11월 14일 |
요약
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
| Group 1: Golimumab | 31.9 Percentage of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
- ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University